Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 6/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364714 | 1.00 | USP30 (0.39) | USP30DGAT1LPLLIPGSYK | |
| SCHEMBL196887 | 0.89 | DGAT1 (0.43) | USP30DGAT1LPLLIPG | |
| SCHEMBL29579430 | 0.89 | DGAT1 (0.43) | USP30DGAT1LPLLIPG | |
| Methane SCHEMBL28521588 | 0.85 | DGAT1 (0.41) | USP30DGAT1LPLLIPG | |
| SCHEMBL23211045 | 0.84 | USP30 (0.47) | USP30DGAT1LPLLIPG | |
| SCHEMBL20791777 | 0.83 | DGAT1 (0.40) | USP30DGAT1LPLLIPG | |
| SCHEMBL20364715 | 0.82 | USP30 (0.35) | USP30DGAT1LPLLIPGFFAR1 | |
| SCHEMBL16787857 | 0.80 | DGAT1 (0.40) | USP30DGAT1LPLLIPGFFAR1 | |
| SCHEMBL30322906 | 0.80 | LPL (0.36) | LPLLIPG | |
| SCHEMBL29082091 | 0.80 | LPL (0.36) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-01 | — | — | US | disclosed |
| EP-3986406-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | USP30 1866/4885DGAT1 1275/4885LPL 2856/4885 |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | USP30 1866/4885DGAT1 1275/4885LPL 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.